Biohm Technologies
Tim Dang is an experienced product management leader currently serving as the Director of Product Management, Growth at 23andMe since February 2011. In this role, Tim has led teams to develop key features that have engaged over 15 million paid customers. Tim also holds advisory positions at BIOHM Health and MasterHealth and serves as an Investor for HealthTech Capital, where evaluations of startup submissions are conducted. Previously, Tim held product leadership roles at Keas and Rhapsody, driving the implementation of wellness programs and innovative music streaming services, respectively. Tim's educational background includes an MBA from Northwestern University's Kellogg School of Management and a BS in Finance from The Wharton School.
This person is not in any teams
Biohm Technologies
Biohm Technologies, based in Cleveland, OH, specializes in the development of targeted microbiome products leveraging the company’s extensive dataset of bacterial and fungal populations in the gut, a departure from the industry's predominant focus on bacteria alone. Biohm’s data-driven methodology, called Symbiont™, is the basis for the creation of award-winning ingredients validated through clinical trials. The company’s flagship ingredient is Mycohsa™, the first data-powered probiotic blend clinically shown to break down digestive biofilms and support optimal levels of both bacteria and yeasts for gut health. Biohm Technologies also offers its state-of-the-art, comprehensive microbiome gut testing kits as a private label solution for brands in the health and wellness space.